References

Key articles

World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015 [internet publication].Full text external link opens in a new window

Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. July 2019 [internet publication].Full text external link opens in a new window

World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].Full text external link opens in a new window

World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. July 2019 [internet publication].Full text external link opens in a new window

European AIDS Clinical Society. European AIDS Clinical Society guidelines: version 10.0. November 2019 [internet publication].Full text external link opens in a new window

Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 2018 [internet publication].Full text external link opens in a new window

Reference articles

1. Centers for Disease Control and Prevention. HIV infection: detection, counseling, and referral. In: Workowski KA, Bolan GA (eds). Sexually transmitted treatment guidelines, 2015. MMWR. 2015 5 June;(64):21-5.Full text external link opens in a new window

2. World Health Organization. HIV/AIDS: online QA. November 2017 [internet publication].Full text external link opens in a new window

3. Worobey M. The origins and diversifications of HIV. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008.

4. Wilson D, Naidoo S, Bekker LG, et al. Handbook of HIV medicine. South Africa: Oxford University Press; 2002.

5. Robertson DL, Anderson JP, Bradac JL, et al. HIV-1 nomenclature proposal. Science. 2000 Apr 7;288(5463):55-6.Abstract external link opens in a new window

6. Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2018 Nov 30. pii: S1473-3099(18)30647-9.Abstract external link opens in a new window

7. Yamaguchi J, McArthur C, Vallari A, et al. Complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):319-22.Abstract external link opens in a new window

8. Gottlieb GS, Raugi DN, Smith RA. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV. 2018 Jul;5(7):e390-9.Abstract external link opens in a new window

9. Fidler S, Fox J. Primary HIV infection: a medical and public health emergency requiring rapid specialist management. Clin Med (Lond). 2016 Apr;16(2):180-3.Full text external link opens in a new windowAbstract external link opens in a new window

10. Joint United Nations Programme on HIV/AIDS. UNAIDS data 2019. 2019 [internet publication].Full text external link opens in a new window

11. GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019 Dec;6(12):e831-9.Full text external link opens in a new windowAbstract external link opens in a new window

12. Li Z, Purcell DW, Sansom SL, et al. Vital signs: HIV transmission along the coninuum of care - United States, 2016. MMWR Morb Mortal Wkly Rep. 2019 Mar 22;68(11):267-72.Full text external link opens in a new windowAbstract external link opens in a new window

13. Centers for Disease Control and Prevention. HIV surveillance report: diagnoses of HIV infection in the United States and dependent areas, 2017; volume 29. November 2018 [internet publication].Full text external link opens in a new window

14. Centers for Disease Control and Prevention. CDC data confirm: progress in HIV prevention has stalled. February 2019 [internet publication].Full text external link opens in a new window

15. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2018 - 2017 data. November 2018 [internet publication].Full text external link opens in a new window

16. Public Health England. Trends in new HIV diagnoses and in people receiving HIV-related care in the United Kingdom: data to the end of December 2018. September 2019 [internet publicaton].Full text external link opens in a new window

17. Public Health England. Prevalence of HIV infection in the UK in 2018. November 2019 [internet publication].Full text external link opens in a new window

18. Brown AE, Mohammed H, Ogaz D, et al. Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or pre-exposure prophylaxis (PrEP)? Euro Surveill. 2017 Jun 22;22(25):30553.Full text external link opens in a new windowAbstract external link opens in a new window

19. Pope M, Hause AT. Transmission, acute HIV-1 infection and the quest to prevent infection. Nat Med. 2003 Jul;9(7):847-52.Abstract external link opens in a new window

20. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008 Sep 1;47(5):712-22.Full text external link opens in a new windowAbstract external link opens in a new window

21. Morris L, Cilliers T. Viral structure, replication, tropism, pathogenesis and natural history. In: Abdool Karim SS, Abdool Karim Q, eds. HIV/AIDS in South Africa. Cambridge University Press; 2005:79-89.

22. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Def Syndr Hum Retrovirol. 1995 Oct 1;10(2):175-6.Abstract external link opens in a new window

23. Varghese B, Maher JE, Peterman TA, et al. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis. 2002 Jan;29(1):38-43.Abstract external link opens in a new window

24. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992 Mar 28;304(6830):809-13.Full text external link opens in a new windowAbstract external link opens in a new window

25. Bell DM. Occupational risk of human immunodeficiency virus infection in health care workers: an overview. Am J Med. 1997 May 19;102(5B):9-15.Abstract external link opens in a new window

26. Cooper ER, Charurat M, Mofenson L, et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94.Abstract external link opens in a new window

27. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016 Nov 13;30(17):2665-83.Full text external link opens in a new windowAbstract external link opens in a new window

28. Tepper NK, Krashin JW, Curtis KM, et al. Update to CDC's US medical eligibility criteria for contraceptive use, 2016: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection. MMWR Morb Mortal Wkly Rep. 2017 Sep 22;66(37):990-4.Full text external link opens in a new windowAbstract external link opens in a new window

29. World Health Organization. Contraceptive eligibility for women at high risk of HIV: guidance statement - recommendations on contraceptive methods used by women at high risk of HIV. 2019 [internet publication].Full text external link opens in a new window

30. Looker KJ, Elmes JAR, Gottlieb SL, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017 Dec;17(12):1303-16.Full text external link opens in a new windowAbstract external link opens in a new window

31. Looker KJ, Welton NJ, Sabin KM, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis. 2020 Feb;20(2):240-9.Full text external link opens in a new windowAbstract external link opens in a new window

32. Riddell J 4th, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA. 2018 Mar 27;319(12):1261-8.Abstract external link opens in a new window

33. Delaugerre C, Rodriguez C, Capitant C, et al. Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. AIDS. 2018;32(16):2353-61.Abstract external link opens in a new window

34. Desai M, Field N, Grant R, et al. Recent advances in pre-exposure prophylaxis for HIV. BMJ. 2017 Dec 11;359:j5011.Full text external link opens in a new windowAbstract external link opens in a new window

35. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2017 update. March 2018 [internet publication].Full text external link opens in a new window

36. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019 Jun 11;321(22):2203-13.Full text external link opens in a new windowAbstract external link opens in a new window

37. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015 [internet publication].Full text external link opens in a new window

38. Cohen SE, Sachdev D, Lee SA, et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018 Nov 29 [Epub ahead of print].Abstract external link opens in a new window

39. Tumarkin E, Siedner MJ, Bogoch II. The BMJ 10-minute consultation: HIV pre-exposure prophylaxis (PrEP). BMJ. 2019 Jan 17;364:k4681.Abstract external link opens in a new window

40. Coelho LE, Torres TS, Veloso VG, et al. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV. 2019 Nov;6(11):e788-9.Abstract external link opens in a new window

41. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 Jul 24;320(4):379-96.Full text external link opens in a new windowAbstract external link opens in a new window

42. Antoni G, Tremblay C, Delaugerre C, et al. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV. 2020 Feb;7(2):e113-20.Abstract external link opens in a new window

43. Grulich AE, Guy R, Amin J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018 Nov;5(11):e629-37.Abstract external link opens in a new window

44. Holt M, Lea T, Mao L, et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17. Lancet HIV. 2018 Aug;5(8):e448-56.Abstract external link opens in a new window

45. Finlayson T, Cha S, Xia M, et al; National HIV Behavioral Surveillance Study Group. Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men - 20 urban areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603.Full text external link opens in a new windowAbstract external link opens in a new window

46. Anglemyer A, Rutherford GW, Horvath T, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009153.Full text external link opens in a new windowAbstract external link opens in a new window

47. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.Full text external link opens in a new windowAbstract external link opens in a new window

48. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016 Jul 12;316(2):171-81.Full text external link opens in a new windowAbstract external link opens in a new window

49. Bavinton BR, Pinto AN, Phanuphak N, et al; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018 Aug;5(8):e438-47.Abstract external link opens in a new window

50. PARTNER Study Group. HIV transmission risk through condomless sex in gay couples with suppressive ART: the PARTNER2 Study extended results in gay men. 2018 [internet publication].Full text external link opens in a new window

51. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019 Jun 15;393(10189):2428-38.Full text external link opens in a new windowAbstract external link opens in a new window

52. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. July 2019 [internet publication].Full text external link opens in a new window

53. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007 Feb 24;369(9562):657-66.Abstract external link opens in a new window

54. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007 Feb 24;369(9562):643-56.Abstract external link opens in a new window

55. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005 Nov;2(11):e298.Full text external link opens in a new windowAbstract external link opens in a new window

56. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systemic review and meta-analysis. AIDS. 2000 Oct 20;14(15):2361-70.Abstract external link opens in a new window

57. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009 Mar 26;360(13):1298-309.Full text external link opens in a new windowAbstract external link opens in a new window

58. Mills E, Cooper C, Anema A, et al. Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11,050 men. HIV Med. 2008 Jul;9(6):332-5.Abstract external link opens in a new window

59. Delany-Moretlwe S, Gray G, Kagee A, et al. AIDS prevention in South Africa. South Afr J HIV Med. 2006;23:13-7.

60. Rubens M, Ramamoorthy V, Saxena A, et al. HIV vaccine: recent advances, current roadblocks, and future directions. J Immunol Res. 2015;2015:560347.Full text external link opens in a new windowAbstract external link opens in a new window

61. Leal L, Lucero C, Gatell JM, et al. New challenges in therapeutic vaccines against HIV infection. Expert Rev Vaccines. 2017 Jun;16(6):587-600.Abstract external link opens in a new window

62. Marshall BDL, Goedel WC, King MRF, et al. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. Lancet HIV. 2018 Sep;5(9):e498-505.Full text external link opens in a new windowAbstract external link opens in a new window

63. Centers for Disease Control and Prevention. Laboratory testing for the diagnosis of HIV infection: updated recommendations. June 2015 [internet publication].Full text external link opens in a new window

64. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection: United States, 2014. MMWR Recomm Rep. 2014;63(RR-03):1-10.Full text external link opens in a new windowAbstract external link opens in a new window

65. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].Full text external link opens in a new window

66. UNAIDS, World Health Organization. UNAIDS/WHO policy statement on HIV testing. June 2004 [internet publication].Full text external link opens in a new window

67. World Health Organization. HIV drug resistance report 2019. July 2019 [internet publication].Full text external link opens in a new window

68. Shepher J, Quinn T. Laboratory testing for HIV infection. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008:101-7.

69. Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15;49(10):1582-90.Full text external link opens in a new windowAbstract external link opens in a new window

70. Aves T, Tambe J, Siemieniuk RA, et al. Antiretroviral resistance testing in HIV-positive people. Cochrane Database Syst Rev. 2018 Nov 9;(11):CD006495.Full text external link opens in a new windowAbstract external link opens in a new window

71. Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: sexual assault and abuse and STDs. June 2015 [internet publication].Full text external link opens in a new window

72. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. July 2017 [internet publication].Full text external link opens in a new window

73. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17;quiz CE1-4.Full text external link opens in a new windowAbstract external link opens in a new window

74. DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 11;66(31):830-2.Full text external link opens in a new windowAbstract external link opens in a new window

75. Pitasi MA, Oraka E, Clark H, et al. HIV testing among transgender women and men - 27 states and Guam, 2014-2015. MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):883-7.Full text external link opens in a new windowAbstract external link opens in a new window

76. Pitasi MA, Delaney KP, Oraka E, et al. Interval since last HIV test for men and women with recent risk for HIV infection - United States, 2006-2016. MMWR Morb Mortal Wkly Rep. 2018 Jun 22;67(24):677-81.Full text external link opens in a new windowAbstract external link opens in a new window

77. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019 Jun 18;321(23):2326-36.Full text external link opens in a new windowAbstract external link opens in a new window

78. Centers for Disease Control and Prevention. CDC health information for international travel (the Yellow Book): HIV infection. June 2019 [internet publication].Full text external link opens in a new window

79. Centers for Disease Control and Prevention. 2018 quick reference guide: recommended laboratory HIV testing algorithm for serum or plasma specimens. January 2018 [internet publication].Full text external link opens in a new window

80. Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: HIV infection - detection, counseling, and referral. June 2015 [internet publication].Full text external link opens in a new window

81. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. September 2017 [internet publication].Full text external link opens in a new window

82. World Health Organization. Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services. December 2016 [internet publication].Full text external link opens in a new window

83. World Health Organization. Consolidated guidelines on HIV testing services. July 2015 [internet publication].Full text external link opens in a new window

84. Cahn P, Madero JS, Arribas J, et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection - 48-week results from the GEMINI studies. Paper presented at: 22nd International AIDS Conference (AIDS 2018). 2018. Amsterdam, Netherlands.Full text external link opens in a new window

85. The Voluntary HIV Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania and Trinidad: a randomised trial. Lancet. 2000 Jul 8;356(9224):103-12.Abstract external link opens in a new window

86. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. September 2019 [internet publication].Full text external link opens in a new window

87. Grobler L, Siegfried N, Visser ME, et al. Nutritional interventions for reducing morbidity and mortality in people with HIV. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD004536.Full text external link opens in a new windowAbstract external link opens in a new window

88. Olsen MF, Abdissa A, Kaestel P, et al. Effects of nutritional supplementation for HIV patients starting antiretroviral treatment: randomised controlled trial in Ethiopia. BMJ. 2014 May 15;348:g3187.Full text external link opens in a new windowAbstract external link opens in a new window

89. Visser ME, Durao S, Sinclair D, et al. Micronutrient supplementation in adults with HIV infection. Cochrane Database Syst Rev. 2017 May 18;(5):CD003650.Full text external link opens in a new windowAbstract external link opens in a new window

90. US Department of Health and Human Services. HIV and immunizations. January 2019 [internet publication].Full text external link opens in a new window

91. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27;373(9):795-807.Full text external link opens in a new windowAbstract external link opens in a new window

92. Mateo-Urdiales A, Johnson S, Smith R, et al. Rapid initiation of antiretroviral therapy for people living with HIV. Cochrane Database Syst Rev. 2019 Jun 17;(6):CD012962.Full text external link opens in a new windowAbstract external link opens in a new window

93. Feng Q, Zhou A, Zou H, et al. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019 Jul 8;366:l4179.Full text external link opens in a new windowAbstract external link opens in a new window

94. National Institute for Health Research. NIHR Signal: Four-drug treatment for HIV offers no benefit over standard three-drug treatment. September 2019 [internet publication].Full text external link opens in a new window

95. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. December 2018 [internet publication].Full text external link opens in a new window

96. Wang H, Lu X, Yang X, et al. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016 Oct;95(41):e5146.Full text external link opens in a new windowAbstract external link opens in a new window

97. World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: second edition June 2016. July 2017 [internet publication].Full text external link opens in a new window

98. Lennox JL, Landovitz RJ, Ribaudo HJ, et al; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;161(7):461-71.Full text external link opens in a new windowAbstract external link opens in a new window

99. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011 Oct 15;204(8):1217-26.Full text external link opens in a new windowAbstract external link opens in a new window

100. Lindegren ML, Kennedy CE, Bain-Brickley D, et al. Integration of HIV/AIDS services with maternal, neonatal and child health, nutrition, and family planning services. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD010119.Full text external link opens in a new windowAbstract external link opens in a new window

101. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: A systematic review and meta-analysis. HIV Med. 2012 Sep;13(8):453-68.Abstract external link opens in a new window

102. Segarra-Newnham M. Osteoporosis and vitamin D deficiency in HIV-positive patients. J Pharm Technol. 2011;27:251-7.

103. Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018 Aug 16;379(7):645-54.Full text external link opens in a new windowAbstract external link opens in a new window

104. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017 Sep 23;390(10101):1499-510.Abstract external link opens in a new window

105. Li L, Tian JH, Yang K, et al. Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection. Cochrane Database Syst Rev. 2014 Jul 26;(7):CD008439.Full text external link opens in a new windowAbstract external link opens in a new window

106. Lalezari JP, Latiff GH, Brinson C, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 2015 Oct;2(10):e427-37.Abstract external link opens in a new window

107. Murgatroyd C, Pirrie L, Tran F, et al. Structure-activity relationships of the human immunodeficiency virus type 1 maturation inhibitor PF-46396. J Virol. 2016 Aug 26;90(18):8181-97.Full text external link opens in a new windowAbstract external link opens in a new window

108. ClinicalTrials.gov. Attachment inhibitor comparison in heavily treatment experienced patients. August 2019 [internet publication].Full text external link opens in a new window

109. Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019 Jul 9;140(2):e98Full text external link opens in a new windowAbstract external link opens in a new window

110. US Department of Health and Human Services Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. September 2019 [internet publication].Full text external link opens in a new window

111. US Department of Health and Human Services. Guidance for non-HIV-specialized providers caring for persons with HIV who have been displaced by disasters (such as hurricane). September 2018 [internet publication].Full text external link opens in a new window

112. Bruce RD, Merlin J, Lum PJ, et al. 2017 HIVMA of IDSA clinical practice guideline for the management of chronic pain in patients living with HIV. Clin Infect Dis. 2017 Oct 30;65(10):e1-37.Full text external link opens in a new windowAbstract external link opens in a new window

113. Tan DHS, Hull MW, Yoong D, et al; Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017 Nov 27;189(47):E1448-58.Full text external link opens in a new windowAbstract external link opens in a new window

114. Centers for Disease Control and Prevention. Recommendations for HIV prevention with adults and adolescents with HIV in the United States, 2014. December 2014 (amended December 2016) [internet publication].Full text external link opens in a new window

115. World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. July 2019 [internet publication].Full text external link opens in a new window

116. World Health Organization. Consolidated guidelines on person-centred HIV patient monitoring and case surveillance. June 2017 [internet publication].Full text external link opens in a new window

117. World Health Organization. Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs. 2016 [internet publication].Full text external link opens in a new window

118. European AIDS Clinical Society. European AIDS Clinical Society guidelines: version 10.0. November 2019 [internet publication].Full text external link opens in a new window

119. Meintjes G, Moorhouse MA, Carmona S, et al. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017 Jul 15;18(1):776.Full text external link opens in a new windowAbstract external link opens in a new window

120. British HIV Association. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). August 2016 [internet publication].Full text external link opens in a new window

121. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003 May 12;163(9):1009-21.Full text external link opens in a new windowAbstract external link opens in a new window

122. O'Connor J, Smith C, Lampe FC, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017 Jul;4(7):e295-302.Full text external link opens in a new windowAbstract external link opens in a new window

123. Nance RM, Delaney JAC, Simoni JM, et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376-84.Full text external link opens in a new windowAbstract external link opens in a new window

124. Teeraananchai S, Kerr SJ, Amin J, et al. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017 Apr;18(4):256-66.Abstract external link opens in a new window

125. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349-56.Full text external link opens in a new windowAbstract external link opens in a new window

126. Engels EA, Yanik EL, Wheeler W, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis. 2017 Aug 15;65(4):636-43.Full text external link opens in a new window

127. Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019 Apr;568(7751):244-8.Abstract external link opens in a new window

128. Mandalia S, Westrop SJ, Beck EJ, et al. Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988-2010. PLoS One. 2012;7(2):e29844.Full text external link opens in a new windowAbstract external link opens in a new window

129. Lawn SD, Wilkinson RJ, Lipman MC, et al. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Resp Crit Care Med. 2008 Apr 1;177(7):680-5.Abstract external link opens in a new window

130. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138(11):1100-12.Full text external link opens in a new windowAbstract external link opens in a new window

131. Losina E, Hyle EP, Borre ED, et al. Projecting 10-yr, 20-yr and lifetime risks of cardiovascular disease in persons living with HIV in the US. Clin Infect Dis. 2017 Oct 15;65(8):1266-71.Abstract external link opens in a new window

132. Beckman JA, Duncan MS, Alcorn CW, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease. Circulation. 2018 Jul 17;138(3):255-65.Full text external link opens in a new windowAbstract external link opens in a new window

133. Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018 Jun;5(6):e291-300.Abstract external link opens in a new window

134. Osibogun O, Ogunmoroti O, Michos ED, et al. HIV/HCV coinfection and the risk of cardiovascular disease: a meta-analysis. J Viral Hepat. 2017 Nov;24(11):998-1004.Abstract external link opens in a new window

135. Howard JFB, Rokx C, Smit C, et al. Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study. Lancet HIV. 2019 Mar;6(3):e173-81.Abstract external link opens in a new window

136. Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015 Mar 15;60(6):941-9.Full text external link opens in a new windowAbstract external link opens in a new window

137. Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015 Dec;22(6):446-51.Abstract external link opens in a new window

138. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009 Jan 2;23(1):41-50.Full text external link opens in a new windowAbstract external link opens in a new window

139. Yanik EL, Napravnik S, Cole SR, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013 Sep;57(5):756-64.Full text external link opens in a new windowAbstract external link opens in a new window

140. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2551-9.Full text external link opens in a new windowAbstract external link opens in a new window

141. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015 Oct 6;163(7):507-18.Full text external link opens in a new windowAbstract external link opens in a new window

142. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014 May 15;28(8):1181-91.Abstract external link opens in a new window

143. Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. Lancet HIV. 2018 Nov;5(11):e647-55.Abstract external link opens in a new window

144. Park LS, Tate JP, Sigel K, et al. Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study. Ann Intern Med. 2018 Jul 17;169(2):87-96.Abstract external link opens in a new window

145. Klein MB, Althoff KN, Jing Y, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016 Nov 1;63(9):1160-7.Full text external link opens in a new windowAbstract external link opens in a new window

146. Chan P, Brew BJ. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep. 2014 Sep;11(3):317-24.Abstract external link opens in a new window

147. Eshun-Wilson I, Siegfried N, Akena DH, et al. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018 Jan 22;(1):CD008525.Full text external link opens in a new windowAbstract external link opens in a new window

148. Monroe AK, Glesby MJ, Brown TT, et al. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015 Feb 1;60(3):453-62.Full text external link opens in a new windowAbstract external link opens in a new window

149. Nduka CU, Stranges S, Kimani PK, et al. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab Res Rev. 2017 Sep;33(6).Abstract external link opens in a new window

150. Bhatia R, Murphy AB, Raper JL, et al. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems. AIDS. 2015 Jan 2;29(1):77-81.Full text external link opens in a new windowAbstract external link opens in a new window

151. Crothers K, Morris A. HIV infection and lung function decline: challenges, clinical implications, and new questions. AIDS. 2013 May 15;27(8):1345-7.Abstract external link opens in a new window

152. Ensink RJH, Kuper H. Is hearing impairment associated with HIV? A systematic review of data from low- and middle-income countries. Trop Med Int Health. 2017 Dec;22(12):1493-504.Abstract external link opens in a new window

153. Kuhar DT, Henderson DK, Struble KA, et al; US Public Health Service Working Group. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92.Full text external link opens in a new windowAbstract external link opens in a new window

154. Centers for Disease Control and Prevention, US Department of Health and Human Services. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV - United States, 2016. April 2018 [internet publication].Full text external link opens in a new window

155. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 2018 [internet publication].Full text external link opens in a new window

156. Brooks JT, Kawwass JF, Smith DK, et al. Effects of antiretroviral therapy to prevent HIV transmission to women in couples attempting conception when the man has HIV infection - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 18;66(32):859-60.Full text external link opens in a new windowAbstract external link opens in a new window

157. Kawwass JF, Smith DK, Kissin DM, et al. Strategies for preventing HIV infection among HIV-uninfected women attempting conception with HIV-infected men - United States. MMWR Morb Mortal Wkly Rep. 2017 Jun 2;66(21):554-7.Full text external link opens in a new windowAbstract external link opens in a new window

158. National Institute for Health and Care Excellence. HIV testing: increasing uptake among people who may have undiagnosed HIV. December 2016 [internet publication].Full text external link opens in a new window

159. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 3;329(5996):1168-74.Full text external link opens in a new windowAbstract external link opens in a new window

160. Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):230-9.Abstract external link opens in a new window

Use of this content is subject to our disclaimer